Search company, investor...
Search

Predict your next investment

Venture Capital
kreaxi.com

See what CB Insights has to offer

Investments

44

Portfolio Exits

6

Funds

1

About Kreaxi

Kreaxi is a management specialist for over 25 years in the investment company with capital of startups and technology with great potential. We invest in the first rounds of tables € 100K to € 2.5M to support entrepreneurs in priming, starting and accelerating their startups.

Kreaxi Headquarters Location

13-15 rue Taitbout

Paris, 75009,

France

+33 1 73 02 89 69

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Kreaxi News

Nosopharm welcomes new members to supervisory board

Jul 11, 2022

Nosopharm welcomes new members to supervisory board Search jobs Nosopharm welcomes new members to supervisory board Jacques Dumas appointed chairman of supervisory board, joined by new members Laurent Fraisse, Sandra Dubos and Martin Lauriot Prevost Lyon, France, July 11, 2022 – Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces several changes to its supervisory board: Jacques Dumas has been appointed as chairman, taking over from Jacques Biton. Laurent Fraisse is replacing Marie-Paule Richard as an independent member and Sandra Dubos joins as the representative of investor Kreaxi, replacing Gwenael Hamon. Martin Lauriot Prevost joins as an historical investor. These appointments will help Nosopharm to establish new strategic partnerships with both public and private companies, to carry out further development of its lead program, NOSO-502, up to Phase 1 clinical studies, and to prepare its next round of financing. The company recently announced the completion and positive results of its preclinical toxicology studies for NOSO-502 , a first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections. “I am delighted to welcome Jacques Dumas as the new chairman of our supervisory board, along with Laurent Fraisse, Sandra Dubos and Martin Lauriot Prevost as new members. I would also like to thank Jacques Biton, Marie-Paule Richard, Gwenaël Hamon and Bernard Rivière, who have helped us achieve key milestones in the development and funding of the company,” said Philippe Villain-Guillot, chairman of the Nosopharm management board. “I am confident that our renewed board will facilitate synergistic collaborations with industrial and academic partners in order to develop our pipeline and push our promising drug discovery programs against infectious diseases, especially in the context of growing antimicrobial resistance.” Jacques Dumas, chairman of the supervisory board Jacques Dumas has 30 years of R&D experience, including the co-invention of two marketed drugs, Nexavar® and Stivarga®. In 2020, Jacques joined Arrakis, an innovative biotech company dedicated to the discovery of small molecules targeting RNA. He is currently its chief scientific officer (CSO) and oversees all R&D functions. From 2015 to 2019, Jacques was CSO at Tetraphase, a publicly-traded company focused on fully synthetic tetracycline antibiotics (acquired by La Jolla in 2020), where he played a key role in the US and EU approvals of eravacycline. Before joining Tetraphase, Jacques was CSO at Idenix (acquired by Merck in 2014) working on liver-targeted nucleosides and their applications in the treatment of Hepatitis C and other viral diseases. From 2007 to 2014, Jacques worked at AstraZeneca, most recently as VP of strategy for the infectious diseases unit, based in Waltham, MA and Bangalore, India. Prior to that he spent 15 years at Bayer Healthcare in Leverkusen, Germany and West Haven, CT. Jacques attended the Ecole Normale Supérieure, France; he holds a Ph.D. in organic chemistry from Paris VI University, France. He also completed a post-doctoral fellowship at Stanford University, California. “I am thrilled to join Nosopharm’s supervisory board as chairman. Infectious diseases are a major cause of global mortality and antimicrobial resistance is growing, making infections much harder to treat. Nosopharm’s unique drug discovery platform, based on the two underexplored antimicrobial-producing bacteria, Photorhabdus and Xenorhabdus, is well positioned to discover first-in-class anti-infectives and help fight antimicrobial resistance.” Laurent Fraisse, independent member Laurent Fraisse is an experienced biotechnology and pharmaceutical executive and a leading expert in infectious diseases, having overseen R&D for large pharmaceutical firms such as Sanofi and Evotec. He also served as chair of the European Federation of Pharmaceutical Industries and Associations’ (EFPIA) Strategic Governing Group dedicated to infectious diseases. In October 2019, Laurent joined the Drugs for Neglected Diseases initative (DNDi) as R&D director and executive team member. In this capacity he drives DNDi’s science strategy and oversees all worldwide research and clinical activities. Laurent joined Sanofi in 1999 after a ten-year tenure as a science leader at Elf Atochem. During his 20 years at Sanofi, he rose to serve as vice president for infectious diseases R&D, addressing medical needs in bacterial, parasitic and viral related infections. He then joined Evotec as executive vice president for infectious diseases with a mission to accelerate the development of the infectious diseases research pipeline and initiate new open innovation R&D initiatives. Laurent graduated from the Ecole Nationale Supérieure d’Agronomie in Rennes, France, with a specialty in biochemistry, and holds a PhD in biotechnology from the Institut National Polytechnique in Toulouse, France. Sandra Dubos, member (representing Kreaxi) Sandra Dubos has more than 12 years experience in advising and supporting innovative companies in life sciences. She started her career as an engineer at Sanofi-Aventis, in charge of developing processes for the purification of natural active ingredients by ultrafiltration. She then spent four years at Alcimed, a marketing and strategy consulting firm, where she carried out both strategic and operational assignments. Before joining Kreaxi in 2018, Sandra was innovation business manager at Bpifrance Financement. At Kreaxi, Sandra manages a portfolio of nearly a dozen companies, half of which are in the health sector. Martin Lauriot Prevost, member Martin Lauriot Prevost is the co-founder of Ozyme, which he managed between 1984 and 2021. The company specializes in the distribution of products for molecular biology, cell biology and immunology. Martin has dual expertise in biology and genetics, and in business management, with degrees in the two areas from the University of Paris VI, France. Today, Martin works on innovative projects in life sciences as well as impactful projects in the digital field. Frédéric Hammel remains on the supervisory board as member, representing Elaia Partners. About Nosopharm Nosopharm is an innovative biotechnology company specialized in anti-infective drug discovery. The company discovers and develops new anti-infective drugs to combat antimicrobial resistance and infectious diseases. Nosopharm developed a unique drug discovery platform based on the biomining of the bacteria Photorhabdus and Xenorhabdus. Nosopharm is the only biotech company to explore these two high-potential bacteria for anti-infective applications. Founded in 2009, Nosopharm is headquartered in Lyon, France, and employs a highly-skilled team of eight. To date, the company has raised a total of €5.9M ($6.4M) in private equity and €8.7M ($9.4M) in non-dilutive funding from France Relance, Bpifrance, IMI and IMI2, the French Ministry of Defense, Region Languedoc-Roussillon and FEDER.

Kreaxi Investments

44 Investments

Kreaxi has made 44 investments. Their latest investment was in Gryzzly as part of their Seed VC on September 9, 2022.

CBI Logo

Kreaxi Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/16/2022

Seed VC

Gryzzly

$1M

Yes

1

7/1/2022

Seed VC

Revcoo

$3.65M

Yes

1

6/2/2022

Series C

Diabeloop

$75M

No

7

5/10/2022

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

3/9/2022

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/16/2022

7/1/2022

6/2/2022

5/10/2022

3/9/2022

Round

Seed VC

Seed VC

Series C

Seed VC

Seed VC

Company

Gryzzly

Revcoo

Diabeloop

Subscribe to see more

Subscribe to see more

Amount

$1M

$3.65M

$75M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

7

10

10

Kreaxi Portfolio Exits

6 Portfolio Exits

Kreaxi has 6 portfolio exits. Their latest portfolio exit was Tilkee on February 22, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/22/2022

Acquired

$99M

1

10/6/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

9/28/2021

Shareholder Liquidity

Subscribe to see more

$99M

Subscribe to see more

10

3/16/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

9/14/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/22/2022

10/6/2021

9/28/2021

3/16/2021

9/14/2020

Exit

Acquired

Acquired

Shareholder Liquidity

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Kreaxi Acquisitions

2 Acquisitions

Kreaxi acquired 2 companies. Their latest acquisition was Banexi Ventures on November 18, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/18/2016

$99M

Merger

1

11/18/2016

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/18/2016

11/18/2016

Investment Stage

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

Note

Merger

Subscribe to see more

Sources

1

10

Kreaxi Fund History

1 Fund History

Kreaxi has 1 fund, including ARAC III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

ARAC III

$32.73M

1

Closing Date

Fund

ARAC III

Fund Type

Status

Amount

$32.73M

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.